Submitted for Publication: November 5, 2010; final revision received February 11, 2011; accepted March 13, 2011.
Published Online: May 9, 2011. doi:10.1001/archophthalmol.2011.112
Financial Disclosure: Dr Crabb received unrestricted financial support from Pfizer. Dr Anderson is a consultant for Carl Zeiss Meditec and Pfizer. Dr Garway-Heath is a consultant for and received financial support from Carl Zeiss Meditec and Pfizer. Dr Fredette received financial support from Pfizer.
Funding/Support: This work was chiefly supported by Pfizer with an investigator-initiated research grant and by funding from the Department of Health's National Institute for Health Research Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust and University College London Institute of Ophthalmology. Dr Garway-Heath's chair at University College London is supported by funding from the International Glaucoma Association. Data management was supported in part by a grant from the Fonds de la Recherche en Santé du Québec. Data acquisition was supported in part by a fellowship scholarship from Laval University, unrestricted donations from Carl Zeiss Meditec Humphrey, Welch Allyn, and Allergan, core grant P30 EY014801 from the National Eye Institute, and an unrestricted grant from Research to Prevent Blindness to the Bascom Palmer Eye Institute.
Role of the Sponsors: The sponsors and funding organizations had no role in the design or conduct of this research, data analysis, or writing of the manuscript.
Disclaimer: The views expressed in this article are those of the authors and not necessarily those of the Department of Health.